RxDoctor Payments Data

Laura Mason, NP

Family · Idaho Falls, IDNPI 1902980469

Payments from drug & device makers

$2,356in general payments, 2019–2025

Across 123 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$242
  • Novo Nordisk$237
  • Astellas Pharma US Inc$236
  • Ascend Therapeutics US, LLC$113
  • Amgen$78
  • plus $339 from 12 others

What the payments were for

  • Food & beverage$2,09289%
  • Education$2159%
  • Gifts$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,356 in reported general payments places this provider in the 85th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$20,912
Medicare patients
80
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$36,968
MounjaroTirzepatide29$35,554
TrulicityDulaglutide16$14,867
TirosintLevothyroxine Sodium19$4,752
Levothyroxine Sodium271$1,968
Liothyronine Sodium40$1,912
SynthroidLevothyroxine Sodium38$1,526
Estradiol39$1,340
Armour ThyroidThyroid,pork18$1,314
Duloxetine Hcl50$1,309
ProgesteroneProgesterone, Micronized20$1,210
Omeprazole85$1,189
Np ThyroidThyroid,pork16$997
Bupropion XlBupropion Hcl33$523
Potassium Chloride18$411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$242$50,42245 claims
Novo NordiskOzempic$237$36,96830 claims
AbbVieSynthroid, Armour Thyroid$1,111$2,84056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Idaho.

Other family in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →